Results 141 to 150 of about 83,979 (257)

Cancer Incidence in People With Intellectual Disability and Down Syndrome in Australia: A Cohort Study

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective There is inconsistent data on cancer risk in people with intellectual disability. Our primary objective was to compare the incidence of cancer in people with and without intellectual disability. Methods and Analysis A cohort study using linked population‐based administrative and cancer registry data in New South Wales, Australia 2001–
Julian Trofimovs, Claire M. Vajdic, Preeyaporn Srasuebkul, Sallie‐Anne Pearson, Julian N. Trollor   +4 more
wiley   +1 more source

Preoperative Beta‐Hydroxy‐Beta‐Methyl‐Butyrate Supplementation Reduces Mitochondrial Dynamics Proteins and Preserves Hepatic Mitochondrial Function After Partial Hepatectomy in Mice

Acta Physiologica, Volume 242, Issue 5, May 2026.
ABSTRACT Aim The liver exhibits a remarkable regenerative capacity, enabling this organ to maintain homeostasis even after significant injury. However, hepatic regeneration requires sufficient energy to sustain cellular hypertrophy and proliferation, thus ensuring efficient tissue repair.
A. L. Vieira‐da‐Silva, M. V. Esteca, F. A. Silva, I. A. Divino, F. S. Carneiro, E. R. Ropelle, A. S. Torsoni, I. L. Baptista   +7 more
wiley   +1 more source

Fluorine‐18‐Labeled Nucleotide Analogs Targeting Ecto‐5'‐Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors

Angewandte Chemie, Volume 138, Issue 17, 20 April 2026.
Fluorine‐18‐labeled CD73 inhibitor [18F]PSB‐19427 enables noninvasive PET mapping of CD73 overexpression in triple‐negative breast (TNBC) and pancreatic cancer. For [18F]PSB‐19427, specific binding in human tumor tissues, favorable biodistribution with prolonged blood retention, robust tumor uptake, and superiority to [18F]FDG in a TNBC model ...
Clemens Dobelmann, Constanze C. Schmies, Georg Wilhelm Rolshoven, Mirko Scortichini, Stefan Wagner, Andreas Isaak, Riham M. Idris, Jennifer Dabel, Lucie Grey, Karolina Losenkova, Susanne Moschütz, Haneen Al Hroub, Antje Keim, Sandra Höppner, Jouko Sandholm, Pia Boström, Maija Hollmén, Norbert Sträter, Sven Hermann, Gennady G. Yegutkin, Kenneth A. Jacobson, Sonja Schelhaas, Christa E. Müller, Anna Junker   +23 more
wiley   +2 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Positron Emission Tomography Imaging of Bacterial Infections With an Enterobactin Analog to Monitor Treatment Efficacy With a Catechol Antibiotic

Angewandte Chemie, Volume 138, Issue 17, 20 April 2026.
Synopsis. The [68Ga]GaIII‐TREN‐CAM radiochelate selectively accumulates in Gram‐negative sites of infection and noninvasively monitors treatment response a siderophore antibiotic. ABSTRACT Positron emission tomography (PET) is an emerging tool under clinical investigation for the detection of bacterial infections.
M. Andrey Joaqui‐Joaqui, Phuong Nguyen Tran, Axia Marlin, Fiona Armstrong‐Pavlik, Minhua Cao, Valérie C. Pierre, Eszter Boros   +6 more
wiley   +2 more sources

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3807-3818, May 2026.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye, Jonathan Goldney, Thomas Yates, Francesco Zaccardi, Kamlesh Khunti, Elina Akalestou, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis   +8 more
wiley   +1 more source

Associations of obesity, systemic inflammation, and hyperinsulinemia with the incidence of non‐communicable chronic disease and mortality: A prospective cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3883-3894, May 2026.
Abstract Aims Obesity, systemic inflammation, and hyperinsulinemia are all features of metabolic syndrome and frequently occur together. We aimed to evaluate the association of body mass index (BMI) with incident non‐communicable chronic disease (NCD) or all‐cause mortality, independent of C‐reactive protein (CRP) and fasting insulin.
Natasha Wiebe, Stephanie Thompson, Peter Stenvinkel, Aminu Bello, Matthew T. James, Marcello Tonelli   +5 more
wiley   +1 more source

Effects of intraduodenally applied bile salts on pancreatic secretion [PDF]

, 1993
Lehnert, Peter, Riepl, Rudolf L.
core   +1 more source

cancer Incidence and Mortality in Ardabil: Report of an Ongoing Population-Based Cancer Registry in Iran, 2004-2006 [PDF]

Background: Ardabil cancer registry is the first population-based cancer registry in Iran that was established in 2000. The first report from this registry revealed that Ardabil has one of the highest rate of gastric cardia cancer and the lowest rate of ...
بابایی, مسعود, جعفرزاده, حمید, حکمت, شراره, دیده ور, رضا, رمضانی, رشید, سجادی, علیرضا, شکوهی گوگانی, بهروز, صمدی, فاطمه, عقلمندی, سهیلا, فلاح, مهدی, ملک زاده, رضا, هایوکا, ج, یزدانبد, عباس   +12 more
core  

Economic burden of type 2 diabetes management in France according to clinical characteristics

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4019-4032, May 2026.
Abstract Aim We sought to investigate the treatment, medication patterns, and economic burden of type 2 diabetes (T2D) in France. Materials and Methods This was a descriptive retrospective cross‐sectional study of a representative sample of adults in the national healthcare system claims database in 2022.
Bruno Guerci, Christèle Blanc‐Bisson, Eric Vicaut, Gérard De Pouvourville, Bruno Detournay, Corinne Emery, Isabelle Bureau, Taos Ihaddadene‐Salzgeber, Fleur Levrat‐Guillen, Jean‐Pierre Riveline   +9 more
wiley   +1 more source